



## **Raymond Terrace resident becomes 200<sup>th</sup> patient in radiation therapy NINJA trial coordinated by TROG Cancer Research and Genesis Care**

*This trial milestone coincides with Prostate Cancer Awareness Month*

**Maitland, NSW** – Hunter locals are doing their part to shape the future of international cancer care, as Raymond Terrace resident Phillip Bambach becomes the 200<sup>th</sup> patient to participate in the TROG Cancer Research [18.01 – NINJA](#) clinical trial.

The NINJA trial is focused on using advanced imaging and radiation technology to test the effectiveness of fewer treatments for localised prostate cancer patients.

While traditional radiation treatment can require up to seven weeks of daily treatments, participants in the NINJA trial complete one of two shorter schedules of radiation therapy. For Phillip Bambach, this means five treatments over two weeks.

Radiation Oncologist at Genesis Care and Co-Lead Investigator for the NINJA trial, Professor Jarad Martin said that providing better outcomes to cancer patients easily and accessibly, no matter where they are, is an important step for the future of cancer treatment.

"Clinical trials are how we lift our game in cancer care and are a mission-critical component of modern oncology," Prof. Martin said.

"It is fantastic that patients in regional communities such as Maitland have access to leading-edge clinical trials, right on their doorstep."

Mr. Bambach, who will complete his therapy at GenesisCare Maitland on Friday 9 September 2022, said that being part of this trial opportunity was a no-brainer and a chance to make history.

"When I was offered the chance to be a part of a clinical trial after being diagnosed with prostate cancer, I had no hesitation in saying yes," Phillip said.

"It feels good knowing that being on the trial may help men with prostate cancer in the future."

Prostate cancer remains one of the most common cancers amongst men, and statistical data from the Australian Institute of Health and Welfare demonstrates that the further patients are required to travel to receive treatment, the less likely they are to seek help<sup>1</sup>.

---

<sup>1</sup> <https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/cancer/data>

Falling during the month of Prostate Cancer Awareness Month, CEO of TROG Cancer Research Susan Goode said this milestone also acts as a good reminder to check in with your GP and seek treatment as required.

"Prostate cancer is the third most common cause of cancer-related death in Australia<sup>2</sup>. And early detection and effective treatment can be the difference between a long happy life or poorer outcomes and even death.

"At TROG Cancer Research we are so proud of the work we've done with trials like NINJA to provide more accessible and flexible treatment options for those with cancer," Ms Goode concluded.

The Trans-Tasman Radiation Oncology Group (TROG Cancer Research) is one of the largest clinical trials groups in Australia and New Zealand, and in partnership with oncology providers like GenesisCare, aims for its research to deliver successful clinical outcomes for patients, alongside a reduced social burden.

For patients living in regional areas like the Hunter, this burden often takes the shape of hours-long commutes to and from treatment centres.

The NINJA trial allows patients in the Hunter to be a step closer to receiving world-class treatment with fewer barriers.

By reducing the number of treatment sessions, researchers like Professor Martin hope that more patients will travel to receive the care that they need.

Men with prostate cancer in the Hunter region seeking further information on eligibility criteria can call 1800 316 635 or email [oncology.research@genesiscare.com](mailto:oncology.research@genesiscare.com)

**Imagery can be made available upon request.**

---

#### Interview opportunities:

- **Prof. Jarad Martin:** Co-Lead Investigator of the NINA clinical trial and Radiation Oncologist at GenesisCare Maitland
- **Phillip Bambach:** Patient at GenesisCare Maitland and 200<sup>th</sup> person to participate in the NINJA clinical trial
- **Susan Goode:** CEO of TROG Cancer Research

#### Media contacts:

##### For GenesisCare:

Lauren Coleman | 0413 254 545  
[lauren.coleman@genesiscare.com](mailto:lauren.coleman@genesiscare.com)

##### For TROG:

Hannah-Louise Stretton | 0428 908 868  
[hannah@themarketinggp.com.au](mailto:hannah@themarketinggp.com.au)

---

<sup>2</sup> <https://www.cancer.org.au/cancer-information/types-of-cancer/prostate-cancer>

## About TROG Cancer Research

TROG (the Trans-Tasman Radiation Oncology Group) is a global leader in cancer research and has been successfully improving the outcomes of cancer patients since 1989.

Our mission is to improve treatments and quality of life for cancer patients, and we do so by working collaboratively. We are one of the largest clinical trial groups in Australia and New Zealand and we work with hospitals, universities, cancer centres and the wider community around the world to conduct life-changing research.

TROG Cancer Research's focus is providing hope to people with all cancer types through one treatment, radiation therapy. Our research findings have helped advance the way many cancers are treated worldwide.

<https://trog.com.au/>

<https://www.facebook.com/TROGCancerResearch>

<https://twitter.com/TROGfightcancer>

<https://www.instagram.com/trogcancerresearch>

## About GenesisCare:

Headquartered in Sydney, Australia, GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.

GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare is committed to improving clinical outcomes through new therapies.

Every year, GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 300 locations in the US, 40 locations in Australia, 14 in the UK, and 17 in Spain, with more than 30 new centres under development. The organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the US. For more information, visit [genescare.com](https://www.genescare.com)

<https://www.facebook.com/genescare>

<https://twitter.com/GenesisCare>

<https://www.linkedin.com/company/genescare>